Search Results

Ironshore Therapeutics Inc. today announced the appointments of Lewis Warrington as Chief Medical Officer, Nelson F. Isabel as Chief Financial Officer, Nilay Patel as Chief Legal Officer and Tim Branz as Chief Information Officer.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Ironshore Pharmaceuticals Inc. announced the publication of an original paper in the Journal of Child and Adolescent Psychopharmacology that describes new data showing the effect of JORNAY PM® extended-release capsules CII on caregiver strain as measured by the Caregiver Strain Questionnaire.

Verix (www.verix.com), a global leader in advanced data & analytic solutions for Commercial Operations in the Life Sciences industry, announces that Ironshore Pharmaceuticals Inc. has selected its analytic platform to support the commercialization of Ironshore’s prescription medication, launched in the summer of 2019 in the U.S. market.

In recognition of Attention-Deficit/Hyperactivity Disorder (ADHD) Awareness Month, Ironshore Pharmaceuticals Inc. (Ironshore) has partnered with Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) to sponsor an educational webinar to help elevate awareness of ADHD and highlight the challenges that families experience during the early morning routine.